• Home
  • Sonja Šelemetjev

Sonja Šelemetjev

Organisation Group: Department for Endocrinology and Radioimmunology

Academic Degree: Graduated in Biochemistry, PhD in Molecular biology

Current position: Research Associate

Education: Graduated at Faculty of Chemistry, University of Belgrade in 2004. M. Sc Thesis in Biochemistry finished in 2008. and PhD Thesis in 2014. at Faculty of Biology, University of Belgrade.

Research Field:

Part of the group investigating function and growth of thyroid gland, both in physiological and pathophysiological conditions. The activities focus on the molecular pathogenesis of malignant thyroid tumors.

Membership in International and National Societies:

Member of the Serbian Chemical Society
Member of the Biochemical Society
Member of the European Thyroid Association (European Thyroid Association, ETA)

Other responsibilities:

Member of the INEP Ethics Commission 

Bibliography (2015-2020):

Vrhovac L, Šelemetjev S, Vatić S, Mitrović A, Milošević J, Lolić A, Beletić A, Polović N. Novel approach to the measurement of antithyroglobulin antibodies in human serum –application of the Quartz Crystal Microbalance sensors. Talanta. 2020; https://doi.org/10.1016/j.talanta.2020.121588

Stojanović S, Šelemetjev S, Đorić I, Rončević J, Janković Miljuš J, Živaljević V, Išić Denčić T. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation. Eur J Surg Oncol. 2020; 46(10):1835-1842.

Paunović I, Šelemetjev S, Išić Denčić T, Đorić I, Janković Miljuš J, Rončević J, Cvejić D. Coexistence of of BRAFV600E mutation and EGFR overexpression is highly associated with adverse clinicopathologicalfeatures of papillary thyroid carcinoma. Arch Biol Sci 2020;72(1):37-44.

Rončević J, Đorić I, Šelemetjev S, Janković J, Išić Denčić T, Bozić V, Cvejić D. MMP-9 -1562 C/T single nucleotide polymorphism associates with increased MMP-9 level and activity during papillary thyroid carcinoma progression. Pathology.2019;51(1):55-61.

Šelemetjev S, Bartolome A, Išić Denčić T, Đorić I, Paunović I, Tatić S, Cvejić D. Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression. Int J Exp Pathol. 2018;99(2):87-94.

Išić Denčić T, Bartolome A, Šelemetjev S, Đorić I, Tatić S, Živaljević V, Cvejić D. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients. Exp Mol Pathol. 2018;105(2):181-189.

Šelemetjev S, Savin S, Paunović I, Tatić S, Cvejić D. Concominant high expression of survivin and vascular endothelial growth factor-C is strongly associated with metastatic status of lymph nodes in papillary thyroid carcinoma. J Cancer Res Ther. 2018;14(Supplement):S114-S119.

Šelemetjev S, Đorić I, Paunović I, Tatić S, Cvejić D. Coexpressed high levels of VEGF-C and active MMP-9 are associated with lymphatic spreading and local invasiveness of papillary thyroid carcinoma. Am J Clin Pathol. 2016;146(5):594-602.

Denčić T, Savin S, Šelemetjev S, Paskaš S, Živaljević V, Božić V, Cvejić D. Strong expression of HBME-1 associates with high-risk clinicopathological factors of papillary thyroid carcinoma. Pathol Oncol Res. 2015 July;21(3):735-42.

Šelemetjev S, Savin S, Paunović I, Tatić S, Cvejić D. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance. Wien Klin Wochenschr. 2015 May;127(9-10):337-44.